1 Adverse reactions that occurred in 2% of patients treated with RADICAVA and 2% more frequently in placebo-treated patients 1 Hypersensitivity reactions and cases of anaphylaxis have been reported in postmarketing reports with RADICAVA 1 Discontinuations were not associated with contusion, gait disturbance, or headache in patients treated with RADICAVA 2 No known drug interactions based on in vitro drug interaction studies 1 RADICAVA ORS Was Generally Well Tolerated 1,3 The safety profile of RADICAVA ORS was demonstrated in a 6-month, phase 3, open-label clinical trial in 185 patients
This evidence was confirmed by others showing lower IGF-1 levels in cases [57]
In many advanced cancers, telomerase is reactivated, and both very short and very long telomere states have been linked to disease risk in different contexts
qPCR and Immunofluorescence analysis demonstrated dose-dependent telomere length extension in normal cells through hTERT and telomerase upregulation
The mitochondrial calcium regulator cyclophilin d is an essential component of oestrogen-mediated neuroprotection in amyotrophic lateral sclerosis
Nutrients 4 , 13991440 (2012)